PT  - JOURNAL ARTICLE
AU  - Misra-Press, Anita
ED  - Han, Baohui
TI  - ALTER0302
DP  - 2015 Jun 19
TA  - MD Conference Express
PG  - 16--16
VI  - 15
IP  - 8
4099  - http://mdc.sagepub.com/content/15/8/16.1.short
4100  - http://mdc.sagepub.com/content/15/8/16.1.full
AB  - ALTER0302, a randomized double-blind controlled phase 2 trial, examined the efficacy and safety of anlotinib, a multitargeted tyrosine kinase inhibitor, as third-line therapy for Chinese patients with advanced non–small cell lung cancer. Progression-free survival and objective response rates were increased in all subgroups of patients treated with anlotinib with no associated serious adverse events.